Qinlock Generic Name & Formulations
Qinlock Dosage and Administration
Qinlock Boxed Warnings
Risk of new primary cutaneous malignancies. Perform skin exams prior to initiation and during therapy. Manage suspicious skin lesions with excision and dermatopathologic evaluation. Uncontrolled hypertension: do not initiate. Control BP prior to initiation; monitor and treat during therapy as appropriate. Cardiac dysfunction. Assess ejection fraction by echocardiogram or MUGA scan prior to initiation, during therapy, and as clinically indicated. Permanently discontinue if Grade 3/4 left ventricular systolic dysfunction occurs. Impaired wound healing: withhold for ≥1 week prior to elective surgery; do not give for ≥2 weeks after major surgery and until adequate healing. Safety of resuming therapy after resolution of wound healing complications has not been established. Photosensitivity: limit UV exposure during and for at least 1 week after discontinuation. Moderate or severe hepatic impairment. Severe renal impairment. Embryo-fetal toxicity. Advise females of reproductive potential and males (w. female partners) to use effective contraception during and for ≥1 week after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for ≥1 week after the last dose).
Qinlock Adverse Reactions
Qinlock Clinical Trials
Qinlock Patient Counseling